# BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

> **NCT04777708** · EARLY_PHASE1 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma
- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Refractory Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Nanoplexed Poly I:C BO-112
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04777708
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-13
- **Primary completion:** 2023-03-13
- **Final completion:** 2023-03-13
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Withdrawn by sponsor
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04777708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04777708, "BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04777708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*